Doris Ewurafuah Atta-Poku
Doris Ewurafuah Atta-Poku has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Owusu-Andoh
Independent Researcher
1 shared publication - Charan Pithana Sai Venkata Vijay
Bioclues.org, Kukatpally, Hyderabad 500072, Telangana, India
1 shared publication - Emmanuella Efua Agbeko
Independent Researcher
1 shared publication - Hilary Kenneth Addison
Independent Researcher
1 shared publication - Jerriod Paul Amoako Amoako
Independent Researcher
1 shared publication - Karen Osafo Adjei
Independent Researcher
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Springer Nature in Research Square
Cell-Free Mitochondrial DNA as a Damage-Associated Molecular Pattern and Candidate Biomarker in Sickle Cell Disease Vaso-Occlusive Crisis: A Scoping Review
Background Sickle Cell Disease (SCD) is a chronic inflammatory disease that is continuously characterized by repeated hemolysis, vaso-occlusive crises (VOC), and chronic low-grade inflammatory state which is caused by the DAMPs released from the damaged red blood cells. Cell-free Mitochondrial DNA (cf-mtDNA) is one of these DAMPs due to its capability of activating the formation of neutrophil extracellular traps for the induction of VOC. However, the inflammatory processes and molecular mechanisms of cf-mtDNA in SCD remain unclear, and it is still unexplored as a potential biomarker especially within sub-Saharan African (SSA) populations. This review tried to synthesize the current information regarding cf-mtDNA in SCD and explore its origin, inflammatory processes, and potential uses as a clinical biomarker. Method The scoping review was conducted according to the Guidelines of the Joanna Briggs Institute Reviewer’s Manual and reported in accordance with PRISMA-ScR guidelines. Searches were done in the databases of MEDLINE/Pubmed, Google Scholar, and Scopus with the keywords "sickle cell", "DAMP", and other inflammatory-associated terms. Out of the 1584 articles searched, only 11 fulfilled the requirements for inclusion. Nine studies were conducted in the US while the remaining two studies came from the Netherlands, while no studies included participants from Africa. Results Evidence suggests that cf-mtDNA might come from retained mature sickle erythrocytes and trigger NET formation through the cGAS-STING-TBK1 pathway. Nevertheless, there is limited direct evidence connecting cf-mtDNA to VOC occurrence, severity and response to treatment. Studies also presented evidence about biomarkers related to whole blood mtDNA counts, deletions and heteroplasmy load being more significant than the evidence related to cf-mtDNA itself. Conclusion The current evidence indicates that cf-mtDNA can be regarded both as a DAMP and a biomarker nonspecifically in regard to SCD, however, clinical relevance is yet to be confirmed. Further longitudinal research is necessary to explore the predictive power of cf-mtDNA for VOCs, severity of the disease and therapy efficacy as well as surface its relation with other inflammatory DAMPs. To solve these gaps in knowledge additional studies among larger cohorts with sufficient geographic diversity especially from SSA are necessary to be conducted.
- 8 September 2026
- Published by Springer Nature in Research Square
Open AccessCell-Free Mitochondrial DNA as a Damage-Associated Molecular Pattern and Candidate Biomarker in Sickle Cell Disease Vaso-Occlusive Crisis: A Scoping Review
Background Sickle Cell Disease (SCD) is a chronic inflammatory disease that is continuously characterized by repeated hemolysis, vaso-occlusive crises (VOC), and chronic low-grade inflammatory state which is caused by the DAMPs released from the damaged red blood cells. Cell-free Mitochondrial DNA (cf-mtDNA) is one of these DAMPs due to its capability of activating the formation of neutrophil extracellular traps for the induction of VOC. However, the inflammatory processes and molecular mechanisms of cf-mtDNA in SCD remain unclear, and it is still unexplored as a potential biomarker especially within sub-Saharan African (SSA) populations. This review tried to synthesize the current information regarding cf-mtDNA in SCD and explore its origin, inflammatory processes, and potential uses as a clinical biomarker. Method The scoping review was conducted according to the Guidelines of the Joanna Briggs Institute Reviewer’s Manual and reported in accordance with PRISMA-ScR guidelines. Searches were done in the databases of MEDLINE/Pubmed, Google Scholar, and Scopus with the keywords "sickle cell", "DAMP", and other inflammatory-associated terms. Out of the 1584 articles searched, only 11 fulfilled the requirements for inclusion. Nine studies were conducted in the US while the remaining two studies came from the Netherlands, while no studies included participants from Africa. Results Evidence suggests that cf-mtDNA might come from retained mature sickle erythrocytes and trigger NET formation through the cGAS-STING-TBK1 pathway. Nevertheless, there is limited direct evidence connecting cf-mtDNA to VOC occurrence, severity and response to treatment. Studies also presented evidence about biomarkers related to whole blood mtDNA counts, deletions and heteroplasmy load being more significant than the evidence related to cf-mtDNA itself. Conclusion The current evidence indicates that cf-mtDNA can be regarded both as a DAMP and a biomarker nonspecifically in regard to SCD, however, clinical relevance is yet to be confirmed. Further longitudinal research is necessary to explore the predictive power of cf-mtDNA for VOCs, severity of the disease and therapy efficacy as well as surface its relation with other inflammatory DAMPs. To solve these gaps in knowledge additional studies among larger cohorts with sufficient geographic diversity especially from SSA are necessary to be conducted.